ATTRACTING BIGPHARMA’S INVESTMENT IS ONE OF THE MAIN PRIORITIES FOR THE DEVELOPMENT OF THE PHARMACEUTICAL INDUSTRY
Today, on May 21,
the Single distributor of SK-Pharmacy LLP together with partners – Kazakh invest JSC, as well as the Association of International Pharmaceutical Manufacturers in the Republic of Kazakhstan and the Association of Russian Pharmaceutical Manufacturers (ARFP) discussed the development of contract manufacturing, experts in the territory Republic of Kazakhstan.
The meeting was attended by Kazakhstani representative offices: “Adamed Pharma”JSC, “LifeMed” LLP, “Acino Kaz”, “Abbott Kazakhstan” LLP , “Alcon Pharmaceuticals Ltd”, “Astellas Pharma” LLP, “Astrazeneca U-Key Limited” CJSC , Bayer Kaz LLP, B. Brown Medical Kazakhstan LLP, Bezen Healthcare Czech Republic s. r.o ”,“ Boehringer Ingelheim Pharma Gees Mbh ”branch, Berlin-Chemie Ag JSC, Bionorica KAZ LLP, Bausch Health LLP, Woerwag Pharma Gmbh & Co. KG “, ” Gedeon Richter “JSC ,” Gen Ilach ve Saglyk Urunleri Sana ive Tijaret “, GSK KH Kazakhstan LLP, Glenmark Pharmaceuticals LTD, Johnson & Johnson LLC, Innotech International C.AS Laboratories, Ipsen Pharma Kazakhstan LLP, Krka Kazakhstan LLP, Consortium Medexport Italia, Medak Pharma LLP, Organon Central East GmbH, Novartis Pharma Services Ag branch, Novo Nordisk, Orion Pharma East LLP, Prom Medic.Kaz LLP . “, Branch of the Company” Pfizer Export B.V. “, ” Ratiopharm Kazakhstan ” LLP, ” R-Pharm Kazakhstan ” LLP , ” Roche Kazakhstan ” JSC, ” Ordamed “, ” Sandoz Pharmaceuticals D.D “, ” Sanofi -Aventis Kazakhstan, Santen JSC (Santen), San Pharmaceutical Industries Limited, Servier Kazakhstan LLP, Sona Pharm LLP, Sopharma Kazakhstan LLP, Takeda Kazakhstan LLP, Ferrer Kazakhstan LLP , Ferring Pharmaceuticals CA, Fic Medical / Recordati Group, Do Nizhpharm-Kazakhstan LLP, Abbwi Biopharmaceuticals, Ever Neuro Pharma GmbH, Egis Pharmaceutical Plant OJSC, Eli Lilly Vostok S.A. “,” Unipharm, Ink “,” Yadran – Galenski Laboratories ” and other major players in the pharmaceutical market.
It should be noted that the Kazakh pharmaceutical industry, thanks to effective measures of state support, has a huge potential to saturate the domestic market with domestic competitive products, however, today, the share of participation of goods of local origin is significantly lower than imported.
During the meeting of the Council of Foreign Investors, Head of State Kassym-Jomart Tokayev emphasized the importance of developing the domestic pharmaceutical industry, stating that by 2025 Kazakhstan expects to increase the share of its own pharmaceutical production to 50%.
For reference:
Contract manufacturing of medicines and medical devices (hereinafter referred to as contract manufacturing) is the production of medicines and medical devices on a contract basis at the production facilities of manufacturers of medicines and medical devices located in the Republic of Kazakhstan, which ensure full compliance with the requirements of good manufacturing practice (GMP) for medicines.
For 2021, the Single Distributor has 12 direct contracts for 116 names of medicines with representatives of Bigpharma.